BIO Investor Perception Study

8/3/2019 BIO Investor Perception Study

1/16

Welcome to the14th Annual BIO CEO

& Investor Conference


2/16

Alan F. EisenbergExecutive Vice President

Biotechnology Industry Organization (BIO)


3/16

2012 Advisory Committee

Erin Brubaker, VP, WWBD Alliance Management and Head of the AM Centre of Excellence,

GlaxoSmithKline Pharmaceuticals

John Chambers, Managing Director and Head of Healthcare Investment Banking, Roth Capital Partners

Annette Grimaldi, Managing Director, BMO Capital Markets

Michael Hay, Vice President/Product Manager, Sagient Research Systems

Michael G. King, Jr., Managing Director and Senior Biotechnology Analyst, Rodman & Renshaw, LLC

Peter Kolchinksky, PhD, Portfolio Manager, RA Capital Management, LLC

James S.J. Manuso, PhD, MBA, CEO, Astex Pharmaceuticals

Evan McCulloch, Portfolio Manager, Franklin Templeton

Ronald C. Renauld Jr.President and Chief Executive Officer, Idenix Pharmaceuticals

Stephen Sands, Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard

Mark Schoenebaum, Senior Biotech Analyst, ISI Group

Nathan P. Tinker, PhD, Executive Director, New York Biotechnology Association


4/16

Supporting Bank Sponsors


5/16


6/16

BIO Helix Sponsors


7/16

Conference Sponsors

Local Co-Host


8/16

31 New Drug Approvals In 2011& Several More In 2012

Kalydeco (Vertex) Cystic Fibrosis

Erivedge (Roche/Curis) Basal Cell Carcinoma

Inlyta (Pfizer) Renal Cell Carcinoma

2 Drugs Approved With Companion Diagnostics:

Xalkori (Pfizer) NSCLC

Zelboraf (Daiichi Sankyo/Plexxikon/Roche) MetastaticMelanoma

Adcetris (Seattle Genetics)Lymphoma/Hodgkins

Yervoy (BMS) -- Melanoma

A Comeback For FDA Approvals

2012


9/16

Source: BIO Industry Analysis, FactSet

Median-25%

2011

NBI+11%

Stock Performance Of US Biotechs, 2011

New

issues

since

2007

Acquired orbankrupt since

2007Actively traded since 2007


10/16

Stock Performance Of US Biotechs, YTD

Source: BIO Industry Analysis, FactSet

Median+12%

Average

+29%

2012 YTD (as of Feb 10th)

NBI

+14%

New

issues

since

2007

Acquired orbankrupt since

2007Actively traded since 2007


11/16

Majority Of Investors Still Think It

Is A Good Time To Invest In Biotech


12/16

Investors More Focused On Early Stage,

Taking Greater Risk On Less Liquid Cos


13/16

Autoimmune & Oncology Seen As The

Most Attractive Areas To Invest


14/16

Investors Expect MORE

Biotech IPOs In 2012

23

13

17

12

0

5

10

15

20

25

2007 2008 2009 2010 2011

#IPOs

US IPOs


15/16

This presentation may contain forward-lookingstatements. Actual results may differ materially from

such forward-looking statements as a result of various

factors involving uncertainties and risks that vary from

company to company. The specific uncertainties andrisks pertaining to individual publicly-traded companies

at this conference should be reviewed in each

companys Form 10-K report and other such documents

filed with the Securities and Exchange Commission.

Some companies may be clients of the Conference

sponsors or members of BIO.


16/16

Opening Plenary:

Picks and Pans The Buy-Side View for 2012

Moderator:

Stephen Sands - Vice Chairman of US Investment Banking and Global Co-Headof Healthcare, Lazard

Panelists:

Alexander J. Denner, PhD - (former) Managing Director, Icahn Associates

Rajiv Kaul - Portfolio Manager Fidelity Select Biotechnology Portfolio, Fidelity

Greg Martinez - Portfolio Manager, Diamondback Capital Management LLC

Deepa R. Pakianathan, PhD - General Partner, Delphi Ventures

BIO Investor Perception Study

Documents

Transcript of BIO Investor Perception Study